March 23, 2020

**White House Office of Science and Technology Policy**

**COVID-19 High Performance Computing (HPC) Consortium**

This consortium is a unique private-public effort to bring together federal government, industry, and academic leaders to execute complex computational research programs. Researchers are invited to submit COVID-19 related research proposals to the consortium via [this online portal](#), which will then be reviewed for matching with computing resources from one of the partner institutions. An expert panel comprised of top scientists and computing researchers will work with proposers to assess the public health benefit of the work, with emphasis on projects that can ensure rapid results. [XSEDE Website](#)

**National Science Foundation**

**National Science Foundation/Rapid Response Research (RAPID)**

NSF is accepting COVID-19 proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge

- [Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19)](#)
- [Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19)](#)

Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities. Such activities would be funded by the [Computational and Data-Enabled Science and Engineering (CDS&E) program](#) or the [Cyberinfrastructure for Sustained Scientific Innovation (CSSI) program](#).

Proposals in response to this DCL and the NSF DCL on COVID-19 ([NSF 20-052](#)) may also request the use of NSF-funded advanced computing resources such as [Frontera](#), [Stampede2](#), [Bridges](#), [Comet](#) and [JetStream](#).

- [Frequently Asked Questions for Proposers and Awardees](#)
Health and Human Resources
Centers for Disease Control – OSTLTS
Supplemental: Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation’s Health

Funding Opportunity Number: CDC-RFA-OT18-18020202SUPP20

CDC announces the availability of supplemental funding for the organizations that were previously awarded funding under Funding Strategy 1 of CDC-RFA-OT18-1802: "Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation’s Health" in FY18. 2) Organizations meeting this criteria are eligible to apply for new CIO Project Plans specifically intended to address the current outbreak of COVID-19, and may apply according to the Target Population Category (A,B, or C) and Target Population for which they received initial funding in FY18. 3) Link: grants.gov Search on funding number CDC-RFA-OT18-18020202SUPP20

Food and Drug Administration/Office of the Chief Scientist (OCS) and Center for Drug Evaluation and Research (CDER), Office of Medical Policy (OMP)
Drug Development Science Support (U01)

Funding Opportunity Number: FOR-FD-20-010

Announces the intent to release a grant to protect and promote the health of the American public by creating new, applied scientific knowledge, tools, standards and approaches to evaluate products more effectively, predictably and efficiently. NOTE: This is a Forecasted Opportunity. Estimated start date: Sept 01, 2020.

HHS/Biomedical Advanced Research and Development Authority (BARDA)

Updated a broad agency announcement (BAA) to solicit proposals for advanced development and licensure of COVID-19 diagnostics, vaccines, or medicines such as therapeutics or antivirals. BARDA will provide funding, as well as expertise and core services to support development projects selected through this BAA. These products include diagnostic tests (assays); vaccines; therapeutics; medications to help regulate or normalize the immune system (immunomodulators); therapeutics targeting lung repair; medicines that prevent infections either before or after exposure to the virus (pre-exposure or post-exposure prophylaxis); respiratory protective devices; and ventilators. BAA-18-100-SOL-00003-Amendment 13 (March 4, 2020)

HHS/Biomedical Advanced Research and Development Authority (BARDA)

BARDA opened an easy broad agency announcement, an EZ-BAA, seeking diagnostics that utilize platforms already cleared by the FDA, with a viable plan to meet requirements for the FDA to consider emergency use authorization within 12 weeks.

HHS/Office of the Assistant Secretary for Preparedness and Response (ASPR)

Public Health Emergency development of new medical countermeasures

HHS/Centers for Disease Control and Prevention (CDC)

Funding to provide resources to state and local jurisdictions in the coronavirus disease 2019 (COVID-19) response. CDC is contacting State Health Officers to move forward with awarding over $560 million to states, localities, territories, and tribes. CDC will use existing networks to reach out to state and local jurisdictions to access this initial funding. Listing of funding to jurisdictions here.
Frequently Asked Questions for health centers regarding Novel Coronavirus (COVID-19)

National Institutes of Health

NIH/National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of General Medical Sciences (NIGMS)
Administrative Supplementals
Current grantees may be eligible to apply for an administrative supplemental. Contact your program officer to discuss proposed research on SARS-CoV-2/COVID-2019. If it is within the scope of your current grant, an administrative supplement is the best option to obtain additional funding. PA-18-591

NIH/National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of General Medical Sciences (NIGMS)
Notice of Special Interest (NOSI) Regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV)
Notice Number: NOT-AI-20-030
NIAID and NIGMS are collaborating to highlight the urgent need for research on the 2019 novel Coronavirus (2019-nCoV). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against 2019-nCoV.

NIH/National Heart, Lung, and Blood Institute
NHLBI is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Notice Number: NOT-HL-20-757
Topics of specific interest to NHLBI include host response, associations with heart, lung, and blood (HLB) diseases, potential impacts on transfusion safety, and clinical outcomes of infected individuals.

NIH/National Institute on Drug Abuse (NIDA)
Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus
Notice Number: NOT-DA-20-047
NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.

National Institute of Allergy and Infectious Diseases (NIAID)
Coronavirus Resources for Researchers

National Institutes of Health/Office of The Director
Given the fact that COVID-19 and associated impacts continue to evolve, applicants and recipients are strongly encouraged to monitor NIH website for updates.
General Frequently Asked Questions (FAQs) - Proposal Submission and Award Management Related to COVID-19
NIH intends to publish detailed guidance related to administrative flexibilities and associated FAQs.
Notice Number: NOT-OD-20-083

NIH/Fogarty International Center
Coronavirus news, funding and resources for global health researchers

NIH Research
Examples of coronavirus research supported by NIH

World Health Organization
World scientists on COVID-19 met at the World Health Organization’s Geneva headquarters in February 2020 to assess the current level of knowledge about the new virus, agree on critical research questions that need to be answered urgently, and ways to work together to accelerate and fund priority research that can contribute to curtail this outbreak and prepare for future outbreaks. R&D Blueprint

Department of Energy

Department of Energy/COVID-19 Rapid Research Response
DOE is soliciting ideas about how the Department and the National Laboratories might contribute resources for science and technology efforts and collaborations. The Department is encouraging the scientific community and others to consider research questions that underpin COVID-19 response and is requesting input on strategic, priority research directions that may be undertaken using DOE user facilities, computational resources, and enabling infrastructure.
Dear Colleague

DOE Resources Supporting Coronavirus Research

Department of Defense

Defense Logistics Agency (DLA) Troop Support Clothing & Textiles Directorate
Request for Information for PPE in response to COVID-19
Notice ID: SPE1C1-20-R-COVID19
DLA is conducting market research to determine industry capabilities for providing Personal Protective Equipment (PPE) against viral contamination, specifically COVID-19. This is a Request for Information only and not a solicitation for award.

Medical Technology Enterprise Consortium released a pre-announcement on a potential Request for Project Proposals
(RPP) for prototypes of medical and information technologies to combat Covid-19. Potential areas of interest:
• Point-of-care diagnostic that provides rapid and accurate determination on exposure to COVID-19.
• Prophylactic(s)/Therapeutic(s) that can prevent and/or treat in a rapid manner (few hours to 2 days) potentially in a non-hospital environment. Repurposing FDA-approved drugs/biologics for prevention/treatment of COVID-19 or testing of drugs/biologics that have already demonstrated safety in humans are preferred.
• Disease predictive modeling that provides early warning through data capture from several different streams of data to include social media and artificial intelligence (AI) parameter decision tools that would provide actionable information to medical service providers and command structures.
• Patient monitoring, tracking, and management system for in-home or non-hospital environment patient tele-health services to include interface into the Cerner electronic health record.” If the Army does release a formal solicitation, the RPP will be posted to the MTEC website, likely within the next few weeks.

Defense/Army Medical Research Acquisition Activity (USAMRAA)

USAMRAA’s COVID-19 FAQs
This notice addresses general questions associated with proposal submission and award management that may arise in relation to COVID-19. These FAQs will be updated here as more information becomes available

Department of Homeland Security

TSA Industry Assistance with COVID-19
Notice ID: 2020-TSA-IndustryNotice
In the current climate TSA appreciates industry offering to assist the Agency in response to COVID-19. Please submit your offering to the Contracting and Procurement office point of contact, Evelyn S. Tyndell at EngageProcurement@tsa.dhs.gov to ensure appropriate handling.

Department of Justice

DOJ/Office of Community Oriented Policing Services Office (COPS)
COPS has extended the solicitation deadline for several open grant programs due to the potential impact of jurisdictional emergency responses to COVID-19 that may cause reasonable delays for applicants. For detailed individual program information, see the grants page.

DOJ/Office of Justice Programs
OJP announced that solicitations with application due dates before April 1st will have a 2 week extension for submission. OJP Grantee Update #1 COVID-19 Impacts